SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques
© Hu et al; licensee BioMed Central Ltd. 2011
Received: 12 April 2011
Accepted: 13 July 2011
Published: 13 July 2011
HIV infection causes a qualitative and quantitative loss of CD4+ T cell immunity. The institution of anti-retroviral therapy (ART) restores CD4+ T cell responses to many pathogens, but HIV-specific responses remain deficient. Similarly, therapeutic immunization with HIV antigens of chronically infected, ART treated subjects results in poor induction of HIV-specific CD4 responses. In this study, we used a macaque model of ART treatment during chronic infection to study the virologic consequences of SIV antigen stimulation in lymph nodes early after immunization. Rhesus CMV (RhCMV) seropositive, Mamu A*01 positive rhesus macaques were chronically infected with SIVmac251 and treated with ART. The immune and viral responses to SIV gag and RhCMV pp65 antigen immunization in draining lymph nodes and peripheral blood were analyzed. Animals were immunized on contralateral sides with SIV gag and RhCMV pp65 encoding plasmids, which allowed lymph nodes draining each antigen to be obtained at the same time from the same animal for direct comparison.
We observed that both SIV and RhCMV immunizations stimulated transient antigen-specific T cell responses in draining lymph nodes. The RhCMV-specific responses were potent and sustained (50 days post-immunization) in the periphery, while the SIV-specific responses were transient and extinguished quickly. The SIV antigen stimulation selectively induced transient SIV replication in draining lymph nodes.
The data are consistent with a model whereby viral replication in response to SIV antigen stimulation limits the generation of SIV antigen-specific responses and suggests a potential mechanism for the early loss and poor HIV-specific CD4+ T cell response observed in HIV-infected individuals.
CD4+ T cells play a central role in maintaining effective cellular and humoral immune responses by providing help to CD8+ T cells, B cells and innate effectors. The protective role of CD4+ T cell responses in HIV-1 infection has been suggested in previous studies [1, 2]. However, HIV-1 infection results in the progressive loss of CD4+ T cell responses, which is characterized as both a decline in the number of CD4+ T cells and a loss of the functional activity of cells with certain antigenic specificities [3–6]. Although the institution of anti-retroviral therapy (ART) causes viral suppression and recovery of CD4+ T cell response to some common pathogens, HIV-specific CD4 response remains deficient [7, 8]. Similarly, immunization of chronically infected, ART treated patients with HIV antigens does not result in the generation of significant HIV-specific CD4+ T cell responses, suggesting that HIV-specific CD4+ T cells are dysfunctional or preferentially depleted in infection and fail to recover [9–11]. The mechanisms for the failure of HIV antigen immunization to induce HIV-specific CD4+ response are not fully clear .
During an immune response, antigen-presenting cells (APC) activate CD4+ T cells to specific antigen specificities in lymphoid tissue. However, in HIV-1 infection, lymphoid tissue also represents an important site for viral replication, and the interaction between APC and CD4+ T cells may enhance viral replication by multiple mechanisms (reviewed in ). It has been shown that even in the setting of potent regimens of ART, a very low level of viral replication could still be detected [14–16], which may be derived from DC mediated activation of latent virus in memory CD4+ T cells, homeostatic regulation of memory populations, or other long-lived reservoirs . Given that HIV-specific CD4+ memory T cells are preferentially infected by HIV, carrying more viral DNA than total memory cells , we were interested in determining if activation of HIV-specific CD4+ T cells results in viral replication in lymphoid tissue.
We used a rhesus macaque model of ART treatment during chronic infection to study the effects of SIV antigen stimulation in lymph nodes (LNs) compared to a control immunogen on viral replication early after immunization. Mamu A*01+ rhesus macaques were infected with SIVmac251 and after 4 months treated with ART resulting in viral suppression and immune reconstitution. The macaques were also rhesus CMV (RhCMV) seropositive and immunized with an RhCMV immunogen as a control antigen stimulation. Animals were immunized on the left side (both arms and legs) with an SIV gag-encoding expression plasmid and on the right side (both arms and legs) with a RhCMV pp65-encoding expression plasmid, which allowed draining LNs for each antigen to be obtained from the same animal at the same time, allowing for a direct comparison of the effect of SIV and RhCMV antigen stimulation on viral replication.
Infection and immunization of rhesus macaques
ART suppresses viral replication with recovery of peripheral CD4+ T cell counts
SIV and RhCMV antigen immunization induces antigen-specific T cell responses in draining LNs
First, we assessed immune activation induced by antigen immunizations in draining LNs to determine whether the two DNA plasmids were immunogenic. LN mononuclear cells were analyzed for IFN-γ mRNA expression, a major effector cytokine for adaptive immunity. As shown in Figure 3A, an increase in IFN-γ mRNA expression was detected in LNs draining SIV gag and RhCMV pp65 on day 3 post immunization, which was followed by a decline on day 5 to the baseline levels as observed in day 60 LNs (Figure 3A). The result suggests that both DNA plasmids are immunogenic in the rhesus macaques used in this study, which is consistent with previous primate studies where the same DNA plasmids were used and shown to be immunogenic in uninfected macaques [19–25].
We then evaluated the antigen-specific T cell responses in LNs by measuring ex vivo cytokine production of LN mononuclear cells. Cells were stimulated with either SIV gag or RhCMV pp65 peptide pools and production of IL-2, TNF-α and IFN-γ in T cells was determined by polychromatic flow cytometry. Flow cytometry plots for cytokine staining are shown (Figure 3B and 3C). We found that the LN draining SIV gag on day 3, when the immune activation, as measured by IFN-γ mRNA, was the highest, demonstrated potent gag-specific T cell responses based on IL-2, TNF-α and IFN-γ production (Figure 3B and 3D). In contrast, the day 3 LN draining RhCMV pp65 immunization from the same animal, when stimulated by gag peptides, demonstrated no significant response (Figure 3B and 3D). Some multifunctionality of the CD4+ T cell response was observed with approximately 4% expressing three cytokines and 28% expressing two. Similarly, the LNs collected on day 5 post immunization were evaluated for RhCMV-specific T cell responses by stimulating the LN cells with RhCMV-pp65 peptides. A significant RhCMV-specific response was induced in the LN draining the RhCMV pp65 compared to the LN draining the SIV gag immunization site (Figure 3C and 3E). Draining LN responses to SIV immunization decreased by day 5 and from day 7 onwards were similar to the levels observed in day 60-post immunization LNs (Figure 3F and 3G). Taken together, these data suggest that both SIV and RhCMV immunization induced transient antigen-specific T cell responses in draining LNs.
Differential SIV- and RhCMV-specific T cell responses in peripheral blood
SIV antigen immunization induces transient activation of viral replication in the draining LN
Each analysis was performed in the same animal at the same time point where the only difference was the type of immunization drained, thereby avoiding the need to consider confounders present in comparisons between animals. The effects of antigen-specific stimulation on SIV replication were first determined by comparing the levels of SIV doubly spliced RNA in LNMCs draining SIV gag and RhCMV pp65 immunization. Doubly spliced RNA copies were significantly increased in the LNMCs draining the SIV gag immunization compared to those draining the pp65 immunization on days 3, 5, and 7 (Figure 5A). Singly spliced SIV RNA was increased in LNMCs draining SIV gag immunizations on days 5 and 7 (Figure 5B). Similar to the spliced SIV RNAs, all three monkeys demonstrated a statistically significant increase in unspliced viral RNA in LNMCs draining SIV gag immunization compared to RhCMV-pp65 immunization on days 3, 5, and 7 (Figure 5C). At the latter time points, viral replication in the LNMCs draining SIV gag immunizations were not significantly increased compared to LNMCs draining RhCMV pp65 and by day 14, all viral RNAs from LNMCs draining both gag and RhCMV decreased towards baseline levels (Figure 5 A-C). Random effects models were used to adjust for observations from the same animal, which demonstrated that on days 3-7, there was a statistically significant increase in viral replication comparing LNMCs draining SIV gag to those draining RhCMV pp65.
We hypothesized that viral replication would occur soon after immunization and analyzed the early (days 3, 5, and 7) and late (days 9, 11, and 14) time points as groups. Comparing viral replication in all animals induced by gag and pp65 immunization in draining LNMCs at the early time point (days 3 - 7) showed a significant increase by gag immunization; doubly spliced (p = 0.0007), singly spliced (p = 0.029), and unspliced (p = 0.032). These data show that all rhesus macaques demonstrated significant increases, whether analyzed singly or as a group, in viral replication in LNMCs draining SIV gag immunizations. The percent of CD4+ T cells in LNMCs did not differ between LNs draining SIV gag and RhCMV pp65 immunization sites, suggesting that the increase in viral gene expression was not due to differential CD4+ T cell migration to LNs draining gag immunization sites, although we cannot rule out that a larger fraction of cells that trafficked to the gag LN were infected.
No increase in viral load was observed in peripheral blood in response to immunization
Viral loads in periphery during antigen immunization
A biphasic destruction of CD4+ T cells is observed in HIV infection with a massive loss of CD4+ T cells during early infection and a subsequent progressive loss during the chronic stage of infection [29, 30]. Retroviral suppression by ART results in an increase in peripheral CD4+ T cell counts and functional reconstitution of CD4+ T cell responses to many common antigens [31, 32], but HIV-specific CD4+ T cell responses remain deficient . We studied ART-treated, chronic SIV and RhCMV infected rhesus macaques and observed; 1) that both SIV and RhCMV antigen immunizations could induce immune activation and antigen-specific T cell responses in draining LNs. 2) In peripheral blood, the RhCMV-specific response induced by immunization was potent and sustained, whereas the SIV-specific response extinguished quickly. 3) We observed that SIV antigen immunization transiently induced greater levels of SIV replication in draining LNs of all animals compared to RhCMV immunization. In this study, the experimental design of immunizing the same animal with both an SIV antigen and a non-SIV antigen on collateral sides allowed us to directly compare the early immune and viral responses in draining LNs from the same animal at the same time, making it possible to study the effect of antigen stimulation in the context of ART-treated, chronic infection with limited animal numbers. All 3 animals displayed persistent CMV specific T cell responses for 50 days and demonstrated a weak transient SIV specific T cell response in peripheral blood. LNMCs from all animals demonstrated elevated levels of viral replication in response to SIV antigen immunization during the first 7 days after immunization. The data do not prove a causal link between the weak SIV T cell responses and LN viral replication, but are consistent with a hypothesis that SIV antigens induce viral replication that leads to depletion or dysfunction of antigen specific cells leading to a reduction in the strength and longevity of the response.
Pathogenic SIVmac251 infection of rhesus macaques has been well described as one of the preferred experimental models for studying HIV pathogenesis . In this study, all rhesus macaques inoculated with SIVmac251 were Mamu A*01 positive to control for an MHC effect on viral immune responses and disease progression, as well as to aid in the measurement of immune responses by a Mamu A*01 restricted SIV gag tetramer. All macaques established primary SIV infection with typical viral replication dynamics [26, 27, 35], and demonstrated responsiveness to ART with rapid control of viremia (Figure 2A). One animal had occasional blips in viral load that returned to undetectable without changes in therapy. It has been shown that even during the most potent regimens of retroviral suppression, the presence of virus in plasma could be measured by some ultrasensitive assays [14–16]. We believe the blips in FH40 are similar to those observed during therapy in humans, which are not associated with acute infection of cells  and believe that this is representative of a range of low level virus that can be measured during ART . One study identified that HIV-infected subjects that developed blips in viral load had higher instead of lower levels of CD4+ T cell responses to gag . We do not believe that the macaque with blips in viral load is responding differently to ART compared to the animals without measureable blips.
Therapeutic immunization for HIV infection during ART has been studied in SIV-infected rhesus macaques and the immunological and virologic consequences have been investigated in peripheral blood using DNA immunization [39–42], as well as other systems [43–45]. After release from ART, variable immunologic and virologic benefits were reported from no control , temporal control , to long-lasting virologic control . In this study, using RhCMV immunization as a non-SIV control in the same animal, we investigated the immunologic and virologic consequences of immunization with SIV antigen in chronic SIV and RhCMV co-infected, ART treated rhesus macaques focusing on the early response in draining LNs. The plasmids encoding immunogens used for immunization were previously demonstrated to induce potent immune responses in uninfected macaques [19–25]. The RhCMV pp65 plasmid had a greater number of immunostimulatory motifs, which would bias towards the null hypothesis. Moreover, all the comparisons between LNs at each time point were from the same animal collected at the same time, thus allowing us to use each animal as its own control. Also, our study focused on the local responses in draining LN, where the antigen-specific T cell responses and viral replication occur, rather than systemic responses in peripheral blood, as done in most previous studies. In addition, we chose a range of days post immunization covering the early activation of memory T cells and generation of effector responses. Our data show that both SIV and RhCMV antigen immunizations induced transient immune activation and antigen-specific T cell responses in draining LNs. Further measurement of these responses in peripheral blood showed that the RhCMV-specific responses were sustained in PBMC with a rapid onset of cytokine producing CD8+ T cells 3 days post immunization, which was maintained at day 50-post immunization, whereas the immunization induced SIV-specific T cell responses were transient, appearing only on day 9 post-immunization, and extinguished quickly in blood. The peripheral SIV- and RhCMV-specific CD8+ T cell responses were significantly induced compared to pre-immunization levels, supporting that both immunizations induced immune responses. Of interest, a study that repeatedly immunized macaques with long-standing ART-treated SIVmac251 infection induced stronger SIV-specific CD4+ and CD8+ T cell responses in blood . This study used the MVA vector and delivered three immunizations, whereas in our study, only a single gag DNA immunization was used.
HIV-specific CD4+ memory T cells are preferentially infected by HIV, carrying approximately 2- to 5-fold more viral DNA than total memory cells . We hypothesize that during an HIV-specific response, activation of HIV-specific CD4+ T cells, which bear higher amounts of latent virus, results in activation of viral replication in the LN leading to suppression of CD4+ T cells and the HIV-specific responses through multiple mechanisms, while a non-HIV antigen-specific response activates less viral replication allowing more efficient expansion of the response.
We used a naturally RhCMV and experimentally SIVmac251 co-infected and ART treated rhesus macaque model to study the effects of immune stimulation with SIV gag and RhCMV pp65 antigens. The study concentrated on the early immune and viral responses in draining lymphoid organs. Both antigen immunizations were able to induce transient immune activation and antigen-specific T cell responses in draining LNs, but the SIV gag immunization also induced significant viral replication. Following immunization, the SIV response extinguished quickly in peripheral blood, while the RhCMV response was sustained. Our data suggest that SIV antigens, as part of the normal immune response to the virus, leads to T cell stimulation that could potentially lead to viral replication resulting in an impairment in the generation of virus specific CD4+ T cells. It is possible that this mechanism is responsible for the observation that in progressing HIV-infected subjects, CD4-specific responses to HIV antigens are lost early in infection and are difficult to restore or induce. Further studies are needed to determine if there is a causal link between SIV or HIV antigen induced viral replication and impairment of CD4+ T cell responses to the virus.
All animal experiments were performed in strict accordance with the standards of the Association for Assessment and Accreditation of Laboratory Animal Care International and the "Guide for the Care and Use of Laboratory Animals" prepared by the National Research Council. The studies were approved by the University of Pennsylvania and Tulane Institutional Animal Care and Use Committees.
Plasmid DNA expressing the SIV Gag core protein from SIVmac239 (pSIVgag) was used. It is a Rev-independent expression vector designed for a high level of protein expression, as previously described [19, 21–23]. Protein expression is under the transcriptional control of the immediate-early promoter/enhancer of human CMV and the bovine growth hormone polyadenylation signal. Plasmid DNA expressing the RhCMV pp65 protein (pND/pp65-2) was used [20, 24, 25]. The expression of RhCMV pp65 uses the same promoter and polyadenylation signal. The GC and CpG content of the plasmids with inserts are: pSIVgag, 40.5% GC, no CpG-S (GACGTT or AACGTT) motifs and 0.03 potential CpG-N motifs (CCG, CCGG, CGG) per bp; pND-pp65, 51.3% GC, 3 CpG-S motifs and 0.0344 potential CpG-N motifs per bp. Neither contained any human optimal TLR9 immunostimulatory motifs (TGTCGTT). DNA was formulated for injection in 0.15 M citrate buffer and 0.25% bupivicaine at a pH of 6.5.
Infection of rhesus macaques and overview of study
The study timeline is shown in Figure 1. Three RhCMV seropositive Mamu A*01 positive rhesus macaques were intravenously infected with SIVmac251 (1000 TCID50) at time zero. Four months after SIV infection, ART was introduced (subcutaneous PMPA 20 mg/kg/day (Gilead Sciences, Inc) and oral D4T 1 mg/kg/day (Bristol-Meyers Squibb)) and continued until the end of the experiment. The macaques were followed for 5.6 months on ART for recovery of peripheral CD4+ T cell count and viral load suppression. Nine and a half months after infection and 5.6 months after the initiation of ART, each monkey received 2 immunizations with SIV gag encoding DNA [19, 21–23] intramuscularly (i.m.) (2 mg/injection), one in the left arm (triceps muscle) and one in the left leg (quadriceps muscle) and 2 immunizations with RhCMV pp65 encoding plasmid  (2 mg/injection) in the right arm and leg. After immunization, draining LN were sampled at two-time points for each animal by first removing inguinal LNs on each side followed by axillary LN removal from both sides (Macaque FH40 - D3 and D9, Macaque DD05 - D5 and D11, and Macaque CT64 - D7 and D14). On day 60 post immunization, LNs from both sides of each animal, draining SIV gag and RhCMV pp65 immunizations, were collected. Blood was collected every 2-3 weeks throughout the experiment. PBMC were isolated using Ficoll-diatrizoate gradient centrifugation and analyzed by flow cytometry or cryopreserved in 10% DMSO.
Measurement of peripheral viral load and CD4+ T cell counts
Viral RNA in plasma was quantified by a bDNA signal amplification assay (Bayer Inc., version 4.0), specific for SIV, which has a threshold detection limit of 125 copies per ml of plasma .
CD4+ T cell counts using whole blood collected in EDTA were analyzed with anti-CD3 (Clone SP34), anti-CD4 (Clone L200) and anti-CD8 (Clone SK1) fluorochrome-labeled monoclonal antibodies (Beckton-Dickinson) and white blood cell counts, as previously described .
LN biopsy collection and processing were performed as previously described . Briefly, LNs were diced into small pieces using scalpel blades and then pressed through nylon mesh screens and triturated to generate single-cell suspensions. The single cell suspensions were divided into two parts; one was cryopreserved in 10% DMSO and stored in liquid nitrogen and one was frozen as a cell pellet.
In vitro stimulation
Cryopreserved LNMCs or PBMCs were thawed and re-suspended in complete RPMI 1640 supplemented with 10% heat-inactivated serum (HyClone) and L-glutamine (Invitrogen) and rested for two hours at 37°C. Unless otherwise noted, cells were prepared at 1 × 106 cells/ml for in vitro stimulation. For characterizing the SIV- and RhCMV-specific T cell responses, LNMCs or PBMCs were incubated with either SIVmac239 gag 15-mer peptide pool with 11-amino acid overlap, 2 μg/ml each peptide (NIH AIDS Research and Reference Reagent Program) or rhesus CMV pp65 complete peptide pool (15-mers overlapping by 11 amino acids)  at 2 μg/ml for each peptide at 37°C for 6 hours in the presence of Golgi-Stop (0.7 μg/ml), Golgi-Plug (1 μg/ml), and 1 μg/ml of co-stimulatory antibodies anti-CD28 and anti-CD49d (BD Bioscience). Negative control with no stimulation and positive control with PMA (50 ng/ml) and Ionomycin (500 ng/ml) (Sigma-Aldrich) were used.
Cell staining and analysis
After 6 hours of stimulation, cells were washed with washing buffer (PBS with 1% FBS, 0.09% NaN3) and stained with aqua blue dye (Invitrogen) and pre-titrated amounts of fluorochrome-conjugated surface staining antibodies (anti-CD4-PerCP Cy5.5, anti-CD8-FITC, anti-CD14-Pac Blue, anti-CD16-Pac Blue, anti-CD95-PE-Cy5, anti-CD20-Pac Blue (eBioscience), and anti-CD28-ECD (Beckman Coulter) and incubated at 4°C for 20 minutes. Cells were then washed and fixed in 250 μl BD Fixation/Permeabilization solution (BD Biosciences) for 20 minutes at 4°C. After fixation, cells were permeabilized with 1 × BD Perm/Wash buffer and stained with pre-titrated fluorochrome-conjugated antibodies (anti-CD3-APC-Cy7, anti-IL-2-PE, anti-IFN-γ-APC, and anti-TNF-α-PE-Cy7 (BD Biosciences) at 4°C for 45 minutes. Cells were then washed with Perm/Wash buffer and re-suspended in 300 μl PBS, 1% FBS.
Cells were analyzed on an LSR-II flow cytometer (BD Biosciences) equipped for the detection of 18 fluorescence parameters and 200,000 to 500,000 events were obtained. Flow Jo version 8.8.7. (Tree Star) was used to analyze the polychromatic flow data with the analytic gating performed as described [50, 51].
PBMCs were stained with aqua blue; CD14-, CD16-, and CD20-pacific blue; CD3-Cy7-APC; CD8-FITC; and p11C (CTPYDINQM) tetramer-APC (Beckman Coulter) and analyzed on an LSR II flow cytometer.
Primers and probes for real-time PCR
SIV doubly spliced
Forward: 5'- AGGCTAATACATCTTCTGCATCAAAC - 3'
Reverse: 5'- GGGTCCTGTTGGGTATGAGTCTA - 3'
Probe: 5' - CCACCCTCTTATTTCC - 3'
SIV singly spliced
Forward: 5'- AGAGGCCTCCGGTTGCA-3'
Reverse: 5'- CCTTCCCCTTTCCACAATAGC-3'
Forward: 5'- TTGCAGCACCCACAACCA-3'
Probe: 5'- CTCCACAACAAGGACA-3'
Forward: 5'- GTGTGGAGACCATCAAGGAAGAC-3'
Reverse: 5'- CGACAGTTCAGCCATCACTTGGAT-3'
Probe: 5'- AGGTGGTCTCCTCTGAC -3'
Levels of IFN-γ mRNA were quantitated by RT-PCR against a standard curve derived from serial dilutions of in vitro made transcripts using specific primers and probe (Table 2). Copies of IFN-γ mRNA were expressed as per 1 μg of total RNA.
Mean, standard error of the mean, and student's t-test were performed using Microsoft Excel software. For the comparison of viral RNA in LNs draining SIV and RhCMV antigen immunization sites on the same day from the same animal, random effects models were used to adjust for the inherent correction between observations from the same animal. Relative changes were log-transformed for analyses in order to meet normality assumptions. SAS 9.2 was used for the analyses.
Acknowledgements and Funding
We thank Sarah Ratcliffe (University of Pennsylvania) for assistance with the statistical analyses. These studies were supported by a Pilot grant from the University of Pennsylvania Center for AIDS Research, a Public Health Service grant AI-050484 from the National Institute of Allergy and Infectious Diseases, and by the base operating grant to the Tulane National Primate Research Center P51-000164.
- Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997, 278: 1447-1450. 10.1126/science.278.5342.1447.View ArticlePubMedGoogle Scholar
- Wilson JDK, Imami N, Watkins A, Gill J, Hay P, Gazzard B, Westby M, Gotch FM: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis. 2000, 182: 792-798. 10.1086/315764.View ArticlePubMedGoogle Scholar
- Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, Walker BD: Detection of polyfunctional mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis. 2008, 197: 990-999. 10.1086/529048.View ArticlePubMedGoogle Scholar
- Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS: Qualitative-analysis of immune function in patients with the acquired immunodeficiency syndrome - evidence for a selective defect in soluble-antigen recognition. New Engl J Med. 1985, 313: 79-84. 10.1056/NEJM198507113130204.View ArticlePubMedGoogle Scholar
- Miedema F, Petit AJC, Terpstra FG, Schattenkerk J, Dewolf F, Al BJM, Roos M, Lange JMA, Danner SA, Goudsmit J, Schellekens PTA: Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men - HIV affects the immune-system before CD4+ T-helper cell depletion occurs. J Clin Invest. 1988, 82: 1908-1914. 10.1172/JCI113809.PubMed CentralView ArticlePubMedGoogle Scholar
- Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, Casazza JP, Ambrozak DR, Louder M, Ampofo W, Pollakis G, Hill B, Sanga E, Saathoff E, Maboko L, Roederer M, Paxton W, Hoelscher M, Koup RA: Preferential infection and depletion of mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med. 2010, 207: 2869-2881. 10.1084/jem.20100090.PubMed CentralView ArticlePubMedGoogle Scholar
- Cao H, Walker BD: Immunopathogenesis of HIV-1 infection. Clin Dermatol. 2000, 18: 401-410. 10.1016/S0738-081X(99)00135-2.View ArticlePubMedGoogle Scholar
- Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J, Cao HY: Central memory CD4(+) T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004, 173: 2184-2189.View ArticlePubMedGoogle Scholar
- Krowka JF, Stites DP, Jain S, Steimer KS, Georgenascimento C, Gyenes A, Barr PJ, Hollander H, Moss AR, Homsy JM, Levy JA, Abrams DI: Lymphocyte proliferative responses to human immunodeficiency virus-antigens in vitro. J Clin Invest. 1989, 83: 1198-1203. 10.1172/JCI114001.PubMed CentralView ArticlePubMedGoogle Scholar
- Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi H, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of aids clinical trials group protocol 315. J Infect Dis. 1998, 178: 70-79.View ArticlePubMedGoogle Scholar
- Wahren B, Morfeldtmansson L, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P, Werner A, Kurth R, Gallo R, Bolognesi D: Characteristics of the specific cell-mediated immune-response in human immunodeficiency virus-infection. J Virol. 1987, 61: 2017-2023.PubMed CentralPubMedGoogle Scholar
- Gudmundsdotter L, Sjodin A, Bostrom AC, Hejdeman B, Theve-Palm R, Alaeus A, Lidman K, Wahren B: Therapeutic immunization for HIV. Springer Semin Immunopathol. 2006, 28: 221-230. 10.1007/s00281-006-0029-0.View ArticlePubMedGoogle Scholar
- Wu L, KewalRamani VN: Dendritic-cell interactions with HIV: Infection and viral dissemination. Nature Rev Immunol. 2006, 6: 859-868. 10.1038/nri1960.View ArticleGoogle Scholar
- Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001, 344: 472-480. 10.1056/NEJM200102153440702.View ArticlePubMedGoogle Scholar
- Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton N, Watson DC, Quinn TC, Ray SC, Siliciano RF: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol. 2004, 78: 968-979. 10.1128/JVI.78.2.968-979.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D: HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001, 286: 196-207. 10.1001/jama.286.2.196.View ArticlePubMedGoogle Scholar
- Pierson T, McArthur J, Siliciano RF: Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000, 18: 665-708. 10.1146/annurev.immunol.18.1.665.View ArticlePubMedGoogle Scholar
- Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kuntsman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA: HIV preferentially infects HIV-specific CD4(+) T cells. Nature. 2002, 417: 95-98. 10.1038/417095a.View ArticlePubMedGoogle Scholar
- Boyer JD, Robinson TM, Maciag PC, Peng X, Johnson RS, Pavlakis G, Lewis MG, Shen A, Siliciano R, Brown CR, Weiner D, Paterson Y: DNA prime listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology. 2005, 333: 88-101. 10.1016/j.virol.2004.12.026.View ArticlePubMedGoogle Scholar
- Yue Y, Kaur A, Eberhardt MK, Kassis N, Zhou SS, Tarantal AF, Barry PA: Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein b, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol. 2007, 81: 1095-1109. 10.1128/JVI.01708-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, Israel Z, Montefiori DC, Ugen K, Miller N, Kim J, Boyer J, Weiner DB: A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIVmac251 challenge in rhesus macaques. Vaccine. 2003, 21: 629-637. 10.1016/S0264-410X(02)00571-6.View ArticlePubMedGoogle Scholar
- Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK, Muthumani K, Lewis M, Pavlakis G, Felber B, Weiner D: SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol. 2005, 34: 262-270. 10.1111/j.1600-0684.2005.00124.x.View ArticlePubMedGoogle Scholar
- Schadeck EB, Sidhu M, Egan MA, Chong S-Y, Piacente P, Masood A, Garcia-Hand D, Cappello S, Roopchand V, Megati S, Quiroz J, Boyer JD, Felber B, Pavlakis G, Weiner DB, Eldridge JH, Israel ZR: A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIV gag-plasmid DNA vaccine in rhesus macaques. Vaccine. 2006, 24: 4677-4687. 10.1016/j.vaccine.2005.10.035.View ArticlePubMedGoogle Scholar
- Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, Dasgupta A, Li Z, Schmidt KA, Oxford KL, Assaf B, Longmate JA, Diamond DJ, Barry PA: Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol. 2011, 85: 2878-2890. 10.1128/JVI.00883-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Abel K, Strelow L, Yue Y, Eberhardt MK, Schmidt KA, Barry PA: A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine. 2008, 26: 6013-6025. 10.1016/j.vaccine.2008.07.103.PubMed CentralView ArticlePubMedGoogle Scholar
- Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N, Feinberg MB: Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol. 1999, 73: 4829-4839.PubMed CentralPubMedGoogle Scholar
- Harrington PR, Connell MJ, Meeker RB, Johnson PR, Swanstrom R: Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection. J Infect Dis. 2007, 196: 1058-1067. 10.1086/520819.View ArticlePubMedGoogle Scholar
- Park IW, Steen R, Li Y: Characterization of multiple mRNA species of simian immunodeficiency virus from macaques in a CD4+ lymphoid cell line. J Virol. 1991, 65: 2987-2992.PubMed CentralPubMedGoogle Scholar
- Douek DC, Picker LJ, Koup RA: T cell dynamics in HIV-1 infection. Annu Rev Immunol. 2003, 21: 265-304. 10.1146/annurev.immunol.21.120601.141053.View ArticlePubMedGoogle Scholar
- Picker LJ, Watkins DI: HIV pathogenesis: The first cut is the deepest. Nat Immunol. 2005, 6: 430-432.View ArticlePubMedGoogle Scholar
- Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997, 277: 112-116. 10.1126/science.277.5322.112.View ArticlePubMedGoogle Scholar
- Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996, 173: 321-329. 10.1093/infdis/173.2.321.View ArticlePubMedGoogle Scholar
- Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW: Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis. 1999, 179: 329-336. 10.1086/314599.View ArticlePubMedGoogle Scholar
- Letvin NL: Animal-models for AIDS. Immunol Today. 1990, 11: 322-326.View ArticlePubMedGoogle Scholar
- Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD: Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol. 1997, 71: 7518-7525.PubMed CentralPubMedGoogle Scholar
- Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moorman AC, Holmberg SD, Investigators at HOS: Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 2002, 16: 2035-2041. 10.1097/00002030-200210180-00008.View ArticlePubMedGoogle Scholar
- Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ: AIDS Clinical Trial A5244 Team: The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med. 2010, 7: e1000321-10.1371/journal.pmed.1000321.PubMed CentralView ArticlePubMedGoogle Scholar
- Papasavvas E, Kostman J, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan K, Nixon D, Grant R, Poulin JF, McCune J, Mounzer K, Montaner L: HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol. 2006, 26: 40-54. 10.1007/s10875-006-7518-8.View ArticlePubMedGoogle Scholar
- Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C, Jalah R, Patel V, Khan AS, Draghia-Akli R, Pavlakis GN, Felber BK: Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine. 2010, 28: 1962-1974. 10.1016/j.vaccine.2009.10.099.PubMed CentralView ArticlePubMedGoogle Scholar
- Fuller DH, Rajakumar PA, Wu MS, McMahon CW, Shipley T, Fuller JT, Bazmi A, Trichel AM, Allen TM, Mothe B, Haynes JR, Watkins DI, Murphey-Corb M: DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology. 2006, 348: 200-215. 10.1016/j.virol.2005.12.008.View ArticlePubMedGoogle Scholar
- von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK: Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol. 2007, 81: 1972-1979. 10.1128/JVI.01990-06.PubMed CentralView ArticlePubMedGoogle Scholar
- zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves- Duran L, Srivastava R, Otten GR, Rabussay D, Zhang L, Ulmer JB, Barnett SW, Donnelly JJ: A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retrov. 2008, 24: 1103-1116. 10.1089/aid.2008.0055.View ArticleGoogle Scholar
- Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med. 2000, 6: 1140-1146. 10.1038/80481.View ArticlePubMedGoogle Scholar
- Lu W, Wu XX, Lu YZ, Guo WZ, Andrieu JM: Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med. 2003, 9: 27-32. 10.1038/nm806.View ArticlePubMedGoogle Scholar
- De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, Peut V, Rollman E, Loh L, Mason RD, Wilson K, Law MG, Handley AJ, Kent SJ: Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. Plos Pathogens. 2008, 4:Google Scholar
- Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G: Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol. 2002, 169: 5347-5357.View ArticlePubMedGoogle Scholar
- Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, Demartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP: Use of a small molecule ccr5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med. 2003, 198: 1551-1562. 10.1084/jem.20031266.PubMed CentralView ArticlePubMedGoogle Scholar
- Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, Gettie A, Fenamore EA, Sheridan KE, Ho DD, Dailey PJ, Marx PA: Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol. 1998, 72: 7501-7509.PubMed CentralPubMedGoogle Scholar
- Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, Shvetz DE, Chalifoux LV, Sehgal PK, Lackner AA: Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: Highly activated memory CD4+ T cells are rapidly eliminated in early SIV infection in vivo. J Virol. 2000, 74: 57-64. 10.1128/JVI.74.1.57-64.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8(+) T cells. Blood. 2006, 107: 4781-4789. 10.1182/blood-2005-12-4818.PubMed CentralView ArticlePubMedGoogle Scholar
- Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA: Acquisition of direct antiviral effector functions by CMV-specific CD4(+) T lymphocytes with cellular maturation. J Exp Med. 2006, 203: 2865-2877. 10.1084/jem.20052246.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.